NeoTX

Company Overview

Snapshot

Founded in April 2015, NeoTX operates with 11–50 employees. The company has raised $65.5 million across three funding rounds from five investors. A key development occurred in May 2022 when NeoTX acquired InterX, a drug discovery company, enhancing its capabilities in therapeutic molecule design.

Business overview

NeoTX is a biopharmaceutical company focused on immuno-oncology drug development. It leverages its proprietary Selective T cell Redirection (STR) platform to create targeted anticancer immunotherapies. This technology works by binding a genetically engineered bacterial determinant to tumor surfaces and activating immune cells away from the suppressive tumor environment to generate an effective antibacterial response. The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors, serving the pharmaceuticals and life sciences markets.

Strategic signal

In June 2022, NeoTX announced the successful completion of the first stage of its Phase 2a clinical trial for Naptumomab estafenatox in combination with docetaxel for advanced non-small cell lung cancer. This milestone indicates significant progress in its clinical pipeline and validates the potential of its Tumor Targeted Superantigen platform, signaling strong growth potential and advancing its position in the competitive immuno-oncology landscape.

Company Intelligence Q&A

What was the outcome of NeoTX's Phase 2a clinical trial?

In June 2022, NeoTX successfully completed the first stage of its Phase 2a clinical trial for Naptumomab estafenatox in combination with docetaxel for advanced non-small cell lung cancer, showing promising results for new treatment options.

What strategic acquisition did NeoTX make to enhance its drug discovery capabilities?

In May 2022, NeoTX acquired InterX, a drug discovery company. This acquisition expanded NeoTX's capabilities by integrating InterX's advanced proprietary tools for the discovery and design of therapeutic molecules, and brought a pipeline of early-stage drugs.

What leadership changes occurred at NeoTX Therapeutics in early 2022?

In January 2022, NeoTX Therapeutics promoted Marcel Rozencweig to President and appointed Scott Z. Fields as the new Chief Medical Officer, bringing over 30 years of experience in clinical drug development to the team.

When did NeoTX raise its Series C funding round?

In February 2020, NeoTX raised a Series C funding round from investors including Tako Ventures and J. Tomilson Hil. The funds were allocated to advance its selective T-cell redirection molecule for treating advanced and metastatic solid tumors.

When did NeoTX begin its Phase 1b trial in collaboration with AstraZeneca?

In October 2019, NeoTX announced the dosing of the first patient in its Phase 1b trial of Naptumomab estafenatox in combination with AstraZeneca's checkpoint inhibitor durvalumab for advanced or metastatic solid tumors.